Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 05, 2016; 86 (16 Supplement) April 16, 2016

Oligoclonal Immunoglobulin Gamma Bands in the Cerebrospinal Fluid and Risk of Conversion to Secondary Progress in Multiple Sclerosis (P1.370)

Virginija Karrenbauer, Jan Hillert, Ali Manouchehrinia
First published April 4, 2016,
Virginija Karrenbauer
3Dep of Clinical Neuroscience Karolinska institutet and Karolinska University Hospital Stockholm Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Hillert
1Dep of Clinical Neuroscience K8 Karolinska Institute, Neurology R54 Stockholm Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Manouchehrinia
2Dep of Clinical Neuroscience Karolinska Institutet Stockholm Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Oligoclonal Immunoglobulin Gamma Bands in the Cerebrospinal Fluid and Risk of Conversion to Secondary Progress in Multiple Sclerosis (P1.370)
Virginija Karrenbauer, Jan Hillert, Ali Manouchehrinia
Neurology Apr 2016, 86 (16 Supplement) P1.370;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To determine whether the cerebrospinal fluid (CSF) oligoclonal bands (OCB) status in multiple sclerosis (MS) patients is predictive of conversion to secondary progressive MS (SPMS). Background: MS patients without the MS typical OCB distribution of immunoglobulin gamma (IgG) (OCB negative; OCB-) in the CSF have a different genetic background than MS patients with an OCB+ pattern. OCB- patients as a group are significantly different than OCB+ patients in terms of brain lesion distribution and signs of global and regional atrophy. A difference in long-term clinical outcome would be a strong argument for OCB- MS to qualify as a clinically and pathogenically distinct disease entity. Methods: We used data from clinically definite MS patients with known OCB status in the Swedish MS register. Date of birth, MS onset and conversion to SPMS, sex, and duration of exposure to first- and second-line Immunomodulatory treatments (IMTs) was collected. Multivariate Poisson regression models were used to investigate the influence of OCB-status on the risk of conversion to SPMS. Results: 4,728 relapsing-remitting MS (RRMS) patients were included. Overall, 475 (10[percnt]) were OCB- . The proportion of OCB- patients was significantly higher in those who had converted to SPMS than RRMS (11.4[percnt] vs. 9.4[percnt], P=0.02). Median age at conversion was 54.2 years (95[percnt] Confidence Intervals (CI): 53.6 to 55.5) and was not different between the OCB+ and OCB- groups (P= 0.3). While controlling for confounders, only OCB+ males showed higher risk of conversion to SPMS compared with OCB- females (relative risk-ratio: 1.5, 95[percnt] CI: 1.18 to 1.90, P=0.001). Conclusions: OCB- MS patients are just as prone to convert to SPMS as OCB+ MS patients. This indicates that possibly different in physiopathology, OCB- MS is unlikely to mimic other neuroinflammatory MS-like disorders. Our findings emphasize clinical phenotype similarities rather than differences between OCB+ and OCB- MS.

Disclosure: Dr. Karrenbauer has received research support from Novartis and Biogen. Dr. Hillert has received personal compensation for activities with BiogenIdec and Genzyme as an advisory board member, with Merck-Serono as a consultant, and with BiogenIdec, Merck-Serono, Novartis and Teva as a speaker. Dr. Manouchehrinia has nothing to disclose.

Saturday, April 16 2016, 8:30 am-7:00 pm

  • Copyright © 2016 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (2)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise